Merck & Co. Inc. filed the compensation data below on 4/23/2008
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option
|
|
|
Non-Equity
Incentive Plan
|
|
|
Compensation
|
|
All Other
|
|
|
|
|
Name and
Principal
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Stock Awards
|
|
|
Awards
|
|
|
Compensation
|
|
|
Earnings
|
|
Compensation
|
|
Total ($)
|
|
|
|
Position in
2007
|
|
Year
|
|
($)
|
|
|
($)
|
|
|
($) (3)
|
|
|
($) (4)
|
|
|
($) (5)
|
|
|
($) (6)
|
|
($) (7)
|
|
Shown on
Table
|
|
|
|
|
|
Fred Hassan
Chairman of the
Board & Chief
Executive Officer
|
|
2007
|
|
|
$1,670,000
|
(1)
|
|
|
$0
|
|
|
Deferred stock units:
Long-term performance
units:
Transformational incentive:
Performance-based shares:
Total:
|
|
$
|
3,374,238
1,441,960
4,792,103
3,900,919
13,509,220
|
|
|
$
|
8,987,163
|
|
|
Annual incentive:
|
|
$
|
4,033,050
|
|
|
$
|
1,515,382
|
|
$
|
608,937
|
|
$
|
30,323,752
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
1,646,250
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Transformational
incentive:
Total:
|
|
|
4,184,936
2,129,418
3,893,803
10,208,157
|
|
|
|
2,878,072
|
|
|
Annual incentive:
Long-term incentive:
Total:
|
|
|
4,175,000
8,596,698
12,771,698
|
|
|
|
1,520,822
|
|
|
632,927
|
|
|
29,657,926
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert J. Bertolini
Executive Vice
President & Chief
Financial Officer
|
|
2007
|
|
|
908,000
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Transformational
incentive:
Performance-based shares:
Total:
|
|
|
578,048
417,206
1,597,368
1,129,213
3,721,835
|
|
|
|
1,689,620
|
|
|
Annual incentive:
|
|
|
1,183,672
|
|
|
|
553,308
|
|
|
152,875
|
|
|
8,209,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
858,725
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Transformational
incentive:
Total:
|
|
|
1,040,975
616,110
1,297,934
2,955,019
|
|
|
|
786,657
|
|
|
Annual incentive:
Long-term incentive:
Total:
|
|
|
1,400,000
2,882,725
4,282,725
|
|
|
|
883,343
|
|
|
137,712
|
|
|
9,904,181
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrie S. Cox
Executive Vice
President &
President, Global
Pharmaceuticals
|
|
2007
|
|
|
1,037,500
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Transformational
incentive:
Performance-based shares:
Total:
|
|
|
992,609
553,712
1,597,368
1,334,525
4,478,214
|
|
|
|
2,180,888
|
|
|
Annual incentive:
|
|
|
1,327,200
|
|
|
|
544,811
|
|
|
249,687
|
|
|
9,818,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
987,500
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Transformational
incentive:
Total:
|
|
|
1,453,756
817,696
1,297,934
3,569,386
|
|
|
|
1,115,694
|
|
|
Annual incentive:
Long-term incentive:
Total:
|
|
|
1,600,000
3,294,543
4,894,543
|
|
|
|
515,549
|
|
|
222,760
|
|
|
11,305,432
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas P. Koestler, Ph.D.
Executive Vice
President &
President,
Schering-Plough
Research Institute
|
|
2007
|
|
|
726,250
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Performance-based shares:
Total:
|
|
|
899,663
230,711
780,184
1,910,558
|
|
|
|
1,304,013
|
|
|
Annual incentive:
|
|
|
828,345
|
|
|
|
428,785
|
|
|
151,879
|
|
|
5,349,830
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
611,458
|
|
|
|
0
|
|
|
Deferred stock units:
Long-term performance units:
Total:
|
|
|
825,393
340,703
1,166,096
|
|
|
|
268,571
|
|
|
Annual incentive:
Long-term incentive:
Total:
|
|
|
980,000
2,017,908
2,997,908
|
|
|
|
335,551
|
|
|
117,543
|
|
|
5,497,127
|
|
|
|
*The above executive compensation data is an excerpt from the proxy statement filed for
Merck & Co. Inc. on 4/23/2008
|